Stocks Overview

LAST PRICE
27.3300
TODAY'S CHANGE (%)
Trending Up0.1600 (0.5889%)

Bid / Lots
27.1500/ 1
Ask / Lots
27.9700/ 1
Open / Previous Close
27.1400 / 27.1700
Day Range
Low 27.0800
High 27.5750
52 Week Range
Low 25.9200
High 34.6500
Volume
2,406,606
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Tuesday's close: 27.17
Time	Volume	RPRX
09:32 ET	29298	27.18
09:34 ET	4814	27.13
09:36 ET	5344	27.135
09:38 ET	3856	27.15
09:39 ET	2117	27.14
09:41 ET	2500	27.165
09:43 ET	16436	27.27
09:45 ET	11952	27.28
09:48 ET	3903	27.29
09:50 ET	4241	27.35
09:52 ET	3240	27.345
09:54 ET	6075	27.325
09:56 ET	2307	27.335
09:57 ET	4870	27.4
09:59 ET	14109	27.345
10:01 ET	2867	27.36
10:03 ET	10377	27.4
10:06 ET	14215	27.44
10:08 ET	8260	27.43
10:10 ET	4695	27.425
10:12 ET	2381	27.43
10:14 ET	4247	27.45
10:15 ET	1935	27.475
10:17 ET	9949	27.45
10:19 ET	2200	27.45
10:21 ET	6642	27.44
10:24 ET	2741	27.445
10:26 ET	6505	27.445
10:28 ET	6423	27.455
10:30 ET	6809	27.485
10:32 ET	5985	27.455
10:33 ET	1925	27.465
10:35 ET	4202	27.465
10:37 ET	3892	27.485
10:39 ET	1625	27.47
10:42 ET	3396	27.495
10:44 ET	382	27.495
10:46 ET	600	27.49
10:48 ET	2600	27.495
10:50 ET	12405	27.46
10:51 ET	6426	27.45
10:53 ET	3933	27.445
10:55 ET	7533	27.465
10:57 ET	1077	27.465
11:00 ET	7829	27.46
11:02 ET	32475	27.505
11:04 ET	600	27.5
11:06 ET	3242	27.515
11:08 ET	5754	27.55
11:09 ET	2300	27.5
11:11 ET	3605	27.52
11:13 ET	5145	27.525
11:15 ET	14171	27.495
11:18 ET	20555	27.52
11:20 ET	2612	27.49
11:22 ET	27185	27.48
11:24 ET	11039	27.47
11:26 ET	2865	27.4899
11:27 ET	4997	27.45
11:29 ET	4500	27.48
11:31 ET	2900	27.4625
11:33 ET	6709	27.465
11:36 ET	3860	27.5
11:38 ET	2461	27.51
11:40 ET	4200	27.5
11:42 ET	3561	27.51
11:44 ET	700	27.49
11:45 ET	1300	27.495
11:47 ET	1189	27.49
11:49 ET	4800	27.505
11:51 ET	3637	27.495
11:54 ET	100	27.495
11:56 ET	5379	27.445
11:58 ET	4296	27.45
12:00 ET	1025	27.445
12:02 ET	2646	27.455
12:03 ET	1163	27.455
12:05 ET	2547	27.445
12:07 ET	2089	27.45
12:09 ET	3125	27.44
12:12 ET	2044	27.45
12:14 ET	700	27.465
12:16 ET	570	27.46
12:18 ET	700	27.46
12:20 ET	2889	27.465
12:21 ET	3629	27.48
12:23 ET	3652	27.485
12:25 ET	2925	27.465
12:27 ET	3126	27.47
12:30 ET	4418	27.485
12:32 ET	4159	27.48
12:34 ET	1613	27.475
12:36 ET	1905	27.475
12:38 ET	3000	27.48
12:39 ET	1676	27.48
12:41 ET	1076	27.47
12:43 ET	500	27.475
12:45 ET	3511	27.48
12:48 ET	300	27.475
12:50 ET	1600	27.485
12:52 ET	1685	27.485
12:54 ET	4863	27.53
12:56 ET	4396	27.515
12:57 ET	2541	27.52
12:59 ET	1300	27.505
01:01 ET	751	27.505
01:03 ET	4280	27.495
01:06 ET	3350	27.5164
01:08 ET	1393	27.5101
01:10 ET	2146	27.53
01:12 ET	1062	27.5439
01:14 ET	2541	27.54
01:15 ET	2420	27.5401
01:17 ET	4532	27.545
01:19 ET	9463	27.52
01:21 ET	6723	27.525
01:24 ET	8632	27.52
01:26 ET	1602	27.505
01:28 ET	1480	27.5
01:30 ET	6583	27.465
01:32 ET	7208	27.41
01:33 ET	1403	27.4
01:35 ET	7600	27.36
01:37 ET	2360	27.36
01:39 ET	3341	27.345
01:42 ET	12640	27.38
01:44 ET	11278	27.415
01:46 ET	3684	27.405
01:48 ET	6041	27.38
01:50 ET	4569	27.405
01:51 ET	1654	27.405
01:53 ET	600	27.405
01:55 ET	2242	27.41
01:57 ET	1539	27.42
02:00 ET	2462	27.43
02:02 ET	3069	27.415
02:04 ET	16136	27.4
02:06 ET	1019	27.415
02:08 ET	1576	27.415
02:09 ET	3347	27.415
02:11 ET	2484	27.41
02:13 ET	2037	27.415
02:15 ET	2141	27.405
02:18 ET	5290	27.4
02:20 ET	14263	27.42
02:22 ET	6116	27.41
02:24 ET	6577	27.395
02:26 ET	3890	27.385
02:27 ET	4716	27.38
02:29 ET	4955	27.365
02:31 ET	2400	27.3875
02:33 ET	5460	27.365
02:36 ET	1896	27.36
02:38 ET	2356	27.35
02:40 ET	5354	27.35
02:42 ET	1158	27.355
02:44 ET	3055	27.355
02:45 ET	12202	27.35
02:47 ET	2992	27.36
02:49 ET	1200	27.365
02:51 ET	5785	27.38
02:54 ET	3022	27.385
02:56 ET	969	27.385
02:58 ET	5720	27.395
03:00 ET	3024	27.4
03:02 ET	500	27.405
03:03 ET	6529	27.415
03:05 ET	7958	27.415
03:07 ET	12972	27.39
03:09 ET	1450	27.395
03:12 ET	6494	27.395
03:14 ET	4835	27.385
03:16 ET	5223	27.38
03:18 ET	9565	27.39
03:20 ET	3868	27.355
03:21 ET	6114	27.355
03:23 ET	3011	27.37
03:25 ET	1596	27.365
03:27 ET	11407	27.365
03:30 ET	7480	27.355
03:32 ET	9604	27.37
03:34 ET	15529	27.365
03:36 ET	5677	27.375
03:38 ET	13417	27.395
03:39 ET	6404	27.395
03:41 ET	12923	27.37
03:43 ET	14045	27.365
03:45 ET	7883	27.37
03:48 ET	11217	27.36
03:50 ET	14319	27.355
03:52 ET	27423	27.385
03:54 ET	24602	27.365
03:56 ET	49504	27.365
03:57 ET	56155	27.35
03:59 ET	150725	27.33

Data delayed at least 15 minutes.

Today
May 17, 2024
- DJ S&P 500 Futures Steady In Premarket Trading; RBC Bearings, GameStop Lag, from 7:31AM ET on Friday May 17, 2024 by Dow Jones
  7:31AM ET on Friday May 17, 2024 by Dow Jones
May 13, 2024
- Royalty Pharma to Present at Upcoming Investor Conferences, from 8:15AM ET on Monday May 13, 2024 by Dow Jones
  8:15AM ET on Monday May 13, 2024 by Dow Jones

1 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesRPRX Royalty Pharma PLC	16.2B	15.3x	+1.83%
United StatesAMRX Amneal Pharmaceuticals Inc	2.1B	-11.8x	---
United StatesCTLT Catalent Inc	9.9B	-8.5x	---
United StatesJAZZ Jazz Pharmaceuticals PLC	6.7B	21.8x	-3.53%
United StatesMCKPF Mallinckrodt PLC	1.6M	0.0x	---
United StatesPBH Prestige Consumer Healthcare Inc	3.2B	15.5x	---
As of 2024-05-22

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Contact Information

Headquarters: 110 East 59th StreetNEW YORK, NY, United States 10022
Phone: 212-883-0200
Fax: ---

Executives

Chairman of the Board, Chief Executive Officer: Pablo Legorreta
Vice Chairman, Executive Vice President: Christopher Hite
Chief Financial Officer, Executive Vice President: Terrance Coyne
Executive Vice President - Investments and Chief Legal Officer: George Lloyd
Executive Vice President - Research and Investments: Marshall Urist

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$16.2B
Revenue (TTM)	$2.2B
Shares Outstanding	597.4M
Dividend Yield	3.07%
Annual Dividend Rate	0.8400 USD
Ex-Dividend Date	05-16-24
Pay Date	06-14-24
Beta	0.46
EPS	$1.78
Book Value	$14.61
P/E Ratio	15.3x
Price/Sales (TTM)	7.3
Price/Cash Flow (TTM)	13.6x
Operating Margin	41.96%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Royalty Pharma PLC
NASDAQ:RPRXUnited States

Search Criteria

Charts

Recent News

Today

DJ Cytokinetics Falls 10% on Royalty Pharma Transaction, Stock Offer, from 6 hours ago by Dow Jones

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline, from 6 hours ago by Dow Jones

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline, from 6 hours ago by Dow Jones

May 17, 2024

DJ S&P 500 Futures Steady In Premarket Trading; RBC Bearings, GameStop Lag, from 7:31AM ET on Friday May 17, 2024 by Dow Jones

May 13, 2024

Royalty Pharma to Present at Upcoming Investor Conferences, from 8:15AM ET on Monday May 13, 2024 by Dow Jones

Pharmaceuticals - Diversified Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar